Company-reported prevalence

LB-102

Overview

Field	Value
Drug	LB-102 (N-methyl amisulpride)
Indication	Schizophrenia
Disease	Schizophrenia
Company	LB Pharmaceuticals Inc (global rights)
Documents searched	LB Pharmaceuticals website, pipeline page, October 2026; LB Pharmaceuticals website, home page, October 2026; LB Pharmaceuticals corporate presentation, August 11, 2026; LB Pharmaceuticals Form 10-K for 2025, filed March 2026; LB Pharmaceuticals Form 10-Q for the quarter ended June 30, 2026; LB Pharmaceuticals Form S-1, 2025; LB Pharmaceuticals press release, October 10, 2026 (ECNP Congress data); LB Pharmaceuticals press release, August 2026 (second quarter 2026 results); LB Pharmaceuticals press release, July 2026 (NOVA-2 topline timing); LB Pharmaceuticals press release, March 25, 2026 (NOVA-2 initiation); LB Pharmaceuticals press release, January 8, 2025 (NOVA-1 topline results)
Data as of	October 14, 2026
Prepared by	AI research agent (Claude); not yet reviewed by a person

Company statements of prevalence

United States

Prevalence: LB Pharmaceuticals website, October 2026

“Typically diagnosed in the late teen years to early thirties, schizophrenia is a chronic, severe, complex, and debilitating psychiatric disorder that affects approximately 1% of the U.S. population and is a leading cause of disability.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

LB Pharmaceuticals (2026) website, pipeline page, quoted passage highlighted — Captured from the passage on the page (opens in a new tab)

Prevalence: LB Pharmaceuticals Form 10-K for 2025, March 2026

“Schizophrenia is a chronic, severe, complex, and debilitating psychiatric disorder that affects approximately 1% of the U.S. population and is a leading cause of disability.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

LB Pharmaceuticals (2026) Form 10-K for 2025, quoted passage highlighted — Captured from the passage on the page (opens in a new tab)

Prevalence: LB Pharmaceuticals press release, March 2026

“Typically diagnosed in the late teen years to early thirties, schizophrenia is a chronic, severe, complex, and debilitating psychiatric disorder that affects approximately 1% of the U.S. population and is a leading cause of disability.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

LB Pharmaceuticals (2026) press release, March 25, 2026, quoted passage highlighted — Captured from the passage on the page (opens in a new tab)

Number affected: LB Pharmaceuticals corporate presentation, August 2026

“~3M people in the US with schizophrenia” (opens the source at this quote in a new tab)

Cited source: 2.1 The Global Statistics 2025

LB Pharmaceuticals (2026) corporate presentation, August 11, 2026, quoted passage highlighted — Captured from page 12 of 35 (opens in a new tab)

Number affected (predominantly negative symptoms): LB Pharmaceuticals Form 10-K for 2025, March 2026

“It is estimated that up to 60% of people with schizophrenia may have predominantly negative symptoms that are clinically relevant and require treatment equating to approximately 1.3 million people in the United States.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Number affected (cognitive symptoms): LB Pharmaceuticals Form 10-K for 2025, March 2026

“More than 80% of people with schizophrenia have cognitive symptoms of some kind, equating to approximately 1.8 million patients in the United States.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Europe

No evidence found.

Global

No evidence found.

Other countries and regions

No evidence found.

Geography not stated

Number affected (patients, no geography stated): LB Pharmaceuticals corporate presentation, August 2026

“~3M patients” (opens the source at this quote in a new tab)

Cited source: 2.2 Johns Hopkins Medicine 2026

Sources the company cites

The global statistics 2025

Reference as the company lists it

“Schizophrenia Statistics in the U.S. 2025 | Facts about Schizophrenia – The Global Statistics” (opens the source at this quote in a new tab)

Passage carrying the figure

“Schizophrenia remains a serious and complex mental health condition in the U.S., affecting an estimated 3.2 million people, which equates to 1.2% of the adult population.” (opens the source at this quote in a new tab)

The Global Statistics (2025) Schizophrenia Statistics in the U.S. 2025, quoted passage highlighted — Captured from the passage on the page (opens in a new tab)

Johns hopkins medicine 2026

Reference as the company lists it

“https://www.hopkinsmedicine.org/health/wellness-and-prevention/mental-health-disorder-statistics” (opens the source at this quote in a new tab)

Passage carrying the nearest figure

“Approximately 1% of Americans are affected by schizophrenia.” (opens the source at this quote in a new tab)

Johns Hopkins Medicine (2026) Mental Health Disorder Statistics, quoted passage highlighted — Captured from the passage on the page (opens in a new tab)

Overview

1Company statements of prevalence

Prevalence: LB Pharmaceuticals website, October 2026

Prevalence: LB Pharmaceuticals Form 10-K for 2025, March 2026

Prevalence: LB Pharmaceuticals press release, March 2026

Number affected: LB Pharmaceuticals corporate presentation, August 2026

Number affected (predominantly negative symptoms): LB Pharmaceuticals Form 10-K for 2025, March 2026

Number affected (cognitive symptoms): LB Pharmaceuticals Form 10-K for 2025, March 2026

Number affected (patients, no geography stated): LB Pharmaceuticals corporate presentation, August 2026

2Sources the company cites

Reference as the company lists it

Passage carrying the figure

Reference as the company lists it

Passage carrying the nearest figure

3References

Company statements of prevalence

Sources the company cites

References